Eunjung An

Title: Eunjung An: Innovator in Monoclonal Antibodies

Introduction

Eunjung An is a prominent inventor based in Siheung-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies.

Latest Patents

Eunjung An holds a patent for SH3YL1 antibodies, compositions comprising the same, and vectors and uses thereof. This patent relates to SH3YL1 monoclonal antibodies and compositions that include these antibodies. The disclosure also encompasses isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors that contain these nucleic acid molecules, and host cells that incorporate the vectors. Furthermore, the patent outlines methods for modulating an immune response, treating diabetic nephropathy, and addressing non-alcoholic steatosis hepatitis through the administration of SH3YL1 antibodies. Additionally, it includes methods for treating acute kidney injury and inflammatory bowel disease using the same antibodies.

Career Highlights

Eunjung An is currently associated with Celros Biotech, where he continues to advance his research and development efforts. His work has been instrumental in the exploration of therapeutic applications for SH3YL1 antibodies.

Collaborations

Eunjung An collaborates with notable colleagues, including Yun Soo Bae and Jung-Yeon Yoo, contributing to a dynamic research environment.

Conclusion

Eunjung An's innovative work in monoclonal antibodies and his contributions to biotechnology highlight his role as a key inventor in the field. His patent on SH3YL1 antibodies showcases the potential for significant advancements in medical treatments.